BeiGene, Ltd. (BGNE)
| Previous close | 167.39 |
| Open | 169.26 |
| Bid | 168.71 x 100 |
| Ask | 170.55 x 100 |
| Day's range | 169.26 - 171.76 |
| 52-week range | 126.97 - 241.50 |
| Volume | |
| Avg. volume | 212,575 |
| Market cap | 19.227B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
SAN MATEO, Calif., May 14, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data from its hematology portfolio and pipeline at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024. BeiGene has 28 abstracts accepted at EHA2024, with four scheduled for oral presentations.
- Business Wire
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
SAN MATEO, Calif., May 08, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced results from the first quarter 2024 and business highlights.
- Business Wire
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 26, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company’s strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets.
